CA2093946C - Methanediphosphonic acid formulations with ion exchangers - Google Patents
Methanediphosphonic acid formulations with ion exchangers Download PDFInfo
- Publication number
- CA2093946C CA2093946C CA002093946A CA2093946A CA2093946C CA 2093946 C CA2093946 C CA 2093946C CA 002093946 A CA002093946 A CA 002093946A CA 2093946 A CA2093946 A CA 2093946A CA 2093946 C CA2093946 C CA 2093946C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- composition according
- amino
- acid derivative
- methanediphosphonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Abstract
The invention relates to a novel advantageous oral dosage form for methanediphosphonates, especially the active ingredient disodium pamidronate. A preferred dosage form comprises:
a) disodium-3-amino-1-hydroxypropane-1,1-diphosphonate (disodium pamidronate), b) a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group and, where appropriate, c) further pharmaceutically acceptable excipients.
The ingredients can be processed to form tablets, dragées, capsules etc..
a) disodium-3-amino-1-hydroxypropane-1,1-diphosphonate (disodium pamidronate), b) a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group and, where appropriate, c) further pharmaceutically acceptable excipients.
The ingredients can be processed to form tablets, dragées, capsules etc..
Description
Methanedi~phosphonic acid formulations with ion exchangers The invention relates to an especially advantageous oral dosage form for methanediphos-phonic acid derivatives, to processes for the preparation of that dosage form, and to the use of that dosage form in a therapeutic method for the alleviation of disorders of calcium metabolism.
Numerous methanediphosphonic acid derivatives of different structure are known. For example 3-amino-1-hydroxypropane-1,1-diphosphonic acid and its salts, processes for the preparation of that acid, and its commercial use as a calcium complex-forming component of a detergent composition have been described in German Published Patent SpeciFcation No. 2 130 7.94. T'he suitability of the said acid and its salts as a pharmaceutical active ingredient is described in German Published Patent Application No. 2 405 254.
The disodium salt - referred to hereinafter as disodium pamidronate (generic name) - has already undergone clinical investigation as an antihypercalcaemic drug.
Numerous publications demonstrate the pronounced activity of methanediphosphonic acid derivatives against especially serious conditions such as osteoporosis, osteolysis as a sequel to metastasis in bony substance, and Paget's disease.
An antihypercalcaemically active compound should in addition be suitable for long-term therapy which may last up to several months or years. For such long periods of administra-tion it is necessary to provide suitable dosage forms that can be administered by the patient without assistance, outside the clinical area. Peroral dosage forms, such as tablets, drag~es or capsules, can meet those requirements.
From in-vivo findings using rats, the active ingredient disodium pamidronate is known to have a low absorption capacity after oral administration of approximately 0.2 %, see P.H.
Reitsma et al. in Calcified Tissue Int. (1983) 35: 357-361. A high dose of that active ingredient would therefore be necessary in oral dosage forms, but that has disadvantages since in the British Medical J., Volume 295, 1301-1305 (1987), see page 1304, "epigastric complaints" are mentioned in clinical tests carried out on patients after the administration of capsules or tablets comprising disodium pamidronate. Similar problems are known with ~~~'~~Cz~
Numerous methanediphosphonic acid derivatives of different structure are known. For example 3-amino-1-hydroxypropane-1,1-diphosphonic acid and its salts, processes for the preparation of that acid, and its commercial use as a calcium complex-forming component of a detergent composition have been described in German Published Patent SpeciFcation No. 2 130 7.94. T'he suitability of the said acid and its salts as a pharmaceutical active ingredient is described in German Published Patent Application No. 2 405 254.
The disodium salt - referred to hereinafter as disodium pamidronate (generic name) - has already undergone clinical investigation as an antihypercalcaemic drug.
Numerous publications demonstrate the pronounced activity of methanediphosphonic acid derivatives against especially serious conditions such as osteoporosis, osteolysis as a sequel to metastasis in bony substance, and Paget's disease.
An antihypercalcaemically active compound should in addition be suitable for long-term therapy which may last up to several months or years. For such long periods of administra-tion it is necessary to provide suitable dosage forms that can be administered by the patient without assistance, outside the clinical area. Peroral dosage forms, such as tablets, drag~es or capsules, can meet those requirements.
From in-vivo findings using rats, the active ingredient disodium pamidronate is known to have a low absorption capacity after oral administration of approximately 0.2 %, see P.H.
Reitsma et al. in Calcified Tissue Int. (1983) 35: 357-361. A high dose of that active ingredient would therefore be necessary in oral dosage forms, but that has disadvantages since in the British Medical J., Volume 295, 1301-1305 (1987), see page 1304, "epigastric complaints" are mentioned in clinical tests carried out on patients after the administration of capsules or tablets comprising disodium pamidronate. Similar problems are known with ~~~'~~Cz~
other methanediphosphonic acid derivatives. There is therefore a great need for low-dose oral dosage forms with improved gastric tolerance of the active ingredient.
There are described in published European Patent Application No. 421 921 double-coated granules, especially pellets comprising the active ingredient disodium pamidronate that are coated with a hydrophilic elastic inner coating and an enteric outer coating that is soluble in intestinal juice. Those granules or pellets which, introduced into capsules, can be administered orally, are indeed distinguished by improved gastric tolerance. Release is delayed and occurs in the duodenum, after passage through the stomach, as a result of the enteric outer coating being slowly dissolved by the action of intestinal juice, so that absorption of the active ingredient does not occur until that region of the gastrointestinal tract is reached.
In view of the controlled-release effect of that dosage form, however, the active ingredient still has to be administered in high doses (higher than approximately 150 mg of active ingredient per unit dose form) in spite of the risk of damage to the mucosa of the duodenum. Based on the total length of time taken to pass through the gastrointestinal tract, the controlled-release effect has the result of reducing the time available for the absorption process. That reduction in time is compensated by an increase in dose in order to achieve a therapeutically effective reduction in the level of calcium in the plasma in the remaining time available for the absorption process.
The aim of the present invention is the preparation of a low-dose dosage form with prefer-ably less than 150 mg, especially less than 100 mg, of active ingredient per unit dose form.
With such a reduced dose, there is a reduced risk of damage to the.mucosa over the entire gastrointestinal tract and of the occurrence of other complaints, such as nausea.
That aim is achieved by the present invention, which relates to a pharmaceutical composi-tion comprising a) a methanediphosphonic acid derivative of formula:
R~ -C - RZ (I), I
There are described in published European Patent Application No. 421 921 double-coated granules, especially pellets comprising the active ingredient disodium pamidronate that are coated with a hydrophilic elastic inner coating and an enteric outer coating that is soluble in intestinal juice. Those granules or pellets which, introduced into capsules, can be administered orally, are indeed distinguished by improved gastric tolerance. Release is delayed and occurs in the duodenum, after passage through the stomach, as a result of the enteric outer coating being slowly dissolved by the action of intestinal juice, so that absorption of the active ingredient does not occur until that region of the gastrointestinal tract is reached.
In view of the controlled-release effect of that dosage form, however, the active ingredient still has to be administered in high doses (higher than approximately 150 mg of active ingredient per unit dose form) in spite of the risk of damage to the mucosa of the duodenum. Based on the total length of time taken to pass through the gastrointestinal tract, the controlled-release effect has the result of reducing the time available for the absorption process. That reduction in time is compensated by an increase in dose in order to achieve a therapeutically effective reduction in the level of calcium in the plasma in the remaining time available for the absorption process.
The aim of the present invention is the preparation of a low-dose dosage form with prefer-ably less than 150 mg, especially less than 100 mg, of active ingredient per unit dose form.
With such a reduced dose, there is a reduced risk of damage to the.mucosa over the entire gastrointestinal tract and of the occurrence of other complaints, such as nausea.
That aim is achieved by the present invention, which relates to a pharmaceutical composi-tion comprising a) a methanediphosphonic acid derivative of formula:
R~ -C - RZ (I), I
wherein one of R1 and RZ is hydrogen or hydroxy and the other is amino-C1_4alkyl, CZ_salkyleneamino-Cl_4alkyl, N-mono- or N,N-di-Cl_ealkylamino-Cz_4alkyl, CS_.,cycloalkylamino, heteroaryl-C1_4alkyl or N-C1_4alkyl-N-phenylthio-Cl_4alkylamino-Cl_4alkyl, or a salt thereof, b) a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group and, where appropriate, c) further pharmaceutically acceptable excipients.
According to another aspect of the present invention, there is provided a pharmaceutical composition for the oral administration of methanediphosphonic acid derivatives, comprising a) a methanediphosphonic acid derivative of formula:
~ 03H2 R1- ~ -R2 (I ), wherein one of Rl and RZ is hydrogen or hydroxy and the other is amino-C1_4alkyl, CZ_salkyleneamino-C1_4alkyl, N-mono- or N, N-di-C1_8alkylamino-Cz_4alkyl, C5_~cycloalkylamino, heteroaryl-C1_4alkyl or N-C1_4alkyl-N-phenylthio-C1_4alkylamino-C1_4alkyl, or a pharmaceutically acceptable salt of the derivative, and b) particles of a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group.
In an especially preferred embodiment, the pharmaceutical composition comprises disodium pamidronate in a dose per unit dose form of 50-10o mg, especially 50-80 mg, in admixture with the cationic ion exchange resin Duolite~
( Trade Mark of Rohm & Haas ) C 4 6 7 .
The pharmaceutical composition is preferably administrable in the form of tablets, dragees or capsules and is distinguished by an especially marked reduction in the level of calcium in the plasma. In-vivo findings using rats have shown that, with the new dosage form, the capacity for absorption of the active ingredient when methanediphosphonic acid derivatives are administered orally in an oily or aqueous suspension in admixture with an excess of ion exchange resin based on the active ingredient in a ratio by weight of 1:10 is more than six times greater compared with an orally administered aqueous suspension of the active ingredient. The effective dose ascertained from in-vivo findings is approximately 8 mg/kg (p.o.).
The terms and definitions used hereinbefore and hereinafter preferably have the following meanings within the scope of the description of the invention:
The term "pharmaceutical composition" defines mixtures of methanediphosphonic acid derivatives (I) with resin particles of the cationic ion exchanger defined hereinbefore and, where appropriate, customary pharmaceutical excipients, that can be processed into oral dosage forms, such as tablets, capsules or dragees.
The present invention also relates to a process for the preparation of the pharmaceutical composition, which comprises mixing together a) at least one methanediphosphonic acid derivative (I) and 4a b) resin particles of a cationic macroporous ion exchanger based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group and, where appropriate, c) further pharmaceutically acceptable excipients, and further processing the mixture to produce an oral dosage form.
According to another aspect of the present invention, there is provided a process for the preparation of a pharmaceutical composition for the oral administration of a methanediphosphonic acid derivative, which comprises mixing together a) a methanediphosphonic acid derivative of formula I, as described herein, b) resin particles of a cationic ion exchanger based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group, and further processing the mixture to produce an oral dosage form.
In a compound (I), amino-C1_4alkyl is preferably 2-amino-1-ethyl or 3-amino-1-propyl.
CZ_6Alkyleneamino-Cl_4alkyl is preferably 2- (a,w-C2_4alkyleneamino)-1-ethyl, e.g. 2-(1,4-butyleneamino)-1-ethyl.
N-Mono- or N,N-di-C1_ealkylamino-Ca_4alkyl is preferably 2- (N-C1_4alkyl-N-C4_ealkylamino) -1-ethyl, e.g. 2-(N-methyl-N-n-pentylamino)-1-ethyl.
CS_.,Cycloalkylamino is preferably cycloheptyl- or cyclohexyl-amino.
4b Heteroaryl-Cl_4alkyl is preferably azaaryl-C1_4alkyl having five or six ring members, e.g. 2-, 3-, or 4-pyridylmethyl.
N-Cl_4Alky1-N-phenylthio-Cl_4alkylamino-C1_4alkyl is e.g. 2-[N-methyl-N-(2-phenylthio-1-ethyl)-amino]-1-ethyl.
Salts of methanediphosphonic acid derivatives are especially pharmaceutically acceptable salts formed with amines, but are especially alkali metal salts, e.g. sodium or potassium salts.
The following compounds are especially preferred:
3-Amino-1-hydroxypropane-1,1-diphosphonic acid, 4-amino-1-hydroxy-n-butane-1,1-diphosphonic acid, 3-(1,4-butyleneamino)-1-hydroxypropane-1,I-diphosphonic acid, 1-hydroxy-3-(N-methyl-N-n-pentylamino)-propane-1,1-diphosphonic acid, 1-cyclohexylaminomethane-1,1-diphosphonic acid, 1-hydroxy-2-(3-pyridyl)-ethane-1,1-diphosphonic acid, 1-hydroxy-3-[N-methyl-N-(2-phenylthio-1-ethyl)-amino]-propane-1,1-diphosphonic acid and salts of those compounds.
The especially preferred component a) disodium 3-amino-1-hydroxypropane-1,1-diphosphonate (disodium pamidronate) in the pharmaceutical composition is preferably in the form of the crystalline hydrate, preferably the pentahydrate, the preparation and character--s-istic data of which are described in published European Patent Application 177 443.
An advantageous oral dose has about 20-150 mg, especially about 50-100 mg, more especially about 50-80 mg of active ingredient per unit dose form.
Component b) consists of resin particles of a cationic, microporous or, preferably, macro-porous ion exchanger based on a styrenefdivinylbenzene copolymer having an exchange-able aminophosphonate. group. The matrix consists of polymerised styrene swellable in the aqueous phase with divinylbenzene as crosslinking agent and functional aminophos-phonate groups that are charged with exchangeable canons, especially sodium ions.1n the commercial product Duolite~ C 467, the aminophosphonate group consists of the phos-phonic acid methylaminomethyl group (-CH2-NH-CH2-P03H2) in the form of the canon-exchangeable mono- or di-sadium salt (-CH2-NH-CHZ-P03HNa or -CHZ-NH-CH2-P03Na2). The characteristic data of the commercial product Duolite~ C 467 are as follows:
external appearance beige-coloured beads ionic form Nay exchange capacity 1 equivalent per litre (Na+ form) 1.4 equivalents per litre (H~ form) specific weight 1.12 (Na+ form) suspension 740 g/1 particle size ~ 0.3-1 mm swelling capacity 35 % (H+ form ~ Na+ form) The characteristic data were taken from Product Data Sheet DTS 0092 A
(published in June 1991) of Rohm & Haas.
The average particle size of the resin particles is about 1-200 p.m, especially 10-100 p.m.
The crosslinking is about 2-8 °lo, preferably 2-4 °Jo.
In a special embodiment, the mixing ratio of methanediphosphonic acid derivative (I) to resin particles of the ion exchanger is about 1:1 to 1:100, preferably about l:l to 1:20, especially 1:1 to 1:10.
Component c) consists of pharmaceutically acceptable excipients that can be used for the preparation of oral dosage forms, e.g. solid unit dose forms, such as tablets, dragdes, capsules or sachets, but also of liquid dosage forms, such as syrups, drops, suspensions, emulsions etc..
Tablets are obtained by the direct compression of components a) and b) with customary excipients> such as lactose, mannitol, microcrystalline cellulose or talc, or preferably by the compression of granules.
Granules are also solid medicament preparations that comprise the methanediphosphonic acid derivative (I) and the ion exchange resin defined hereinbefore and such excipients as are customary in the pharmaceutical technology of tabletting processes. The granules according to the present invention can also themselves be used as oral dosage forms when introduced, fox example, into capsules or sachets, but they are preferably further processed to form tablets.
Suitable excipients for the preparation of granules are, e.g., pulverulent fillers with flow-regulating properties, e.g. talc, silicon dioxide, e.g. synthetic amorphous dehydrated silicic acid of the type Syloid~(Grace), e.g. SYLOID 244 FP, microcrystalline cellulose, e.g. of the type Avicel~ (FMC Corp.), e.g. the types AVICEL PH 101, 102, 105, RC 5$1 or RC 591, Emcocelp (Mendell Corp.) or Elcema~ (Degussa), carbohydrates such as sugars, sugar alcohols, starch or starch derivatives, e.g. lactose, dextrose, saccharose, glucose, sorbitol; mannitol, xylitol, potato starch, corn starch, rice starch or wheat starch or amylo-pectin, tricalcium phosphate, calcium hydrogen phosphate or magnesium trisilicate, binders such as gelatin, tragacanth, agar, alginic acid, cellulose ethers, e.g. methylcellu-lose, carboxymethylcellulose or hydraxypropylmethylcellulose, polyethylene glycols or ethylene oxide homopolymers, especially having a degree of polymerisation of about 2.0 x 103 - 1.0 x 105 and an approximate molecular weight of about 1.0 x 105 -5.0 x 106, e.g. excipients known by the name of Polyox~ (Union Carbide), polyvinylpyrrolidone or povidones> especially having a mean molecular weight of about 10 000-360 000, polyvinyl alcohol having a degree of hydrolysis of about 95-99 % and a degree of polymerisation of about 500-2500, and agar or gelatin, surface-active substances, e.g. anionic surfactants of the alkyl sulfate type, e.g. sodium, potassium or magnesium n-dodecyl sulfate, n-tetra-decyl sulfate, n-hexadecyl sulfate or n-octadecyl sulfate, of the allcyl ether sulfate type, e.g. sodium, potassium or magnesium n-dodecyloxyethyl sulfate, n-tetradecyloxyethyl sulfate, n-hexadecyloxyethyl sulfate or n-octadecyloxyethyl sulfate, or of the alkane-sulfonate type, e.g. sodium, potassium or magnesium n-dodecanesulfonate, n-tetradecane--sulfonate, n-hexadecanesulfonate or n-octadecanesulfonate, non-ionic surfactants of the fatty acid polyhydroxyalcohol ester type, such as sorbitan mono-laurate, -oleate, -stearate or -palmitate, sorbitan tristearate or trioleate, polyoxyethylene adducts of fatty acid poly-hydroxyalcohol esters, such as polyoxyethylene sorbitan mono-laurate, -oleate, -stearate, -palmitate, tristearate or trioleate, polyethylene glycol fatty acid esters, such as poly-oxyethyl stearate, polyethylene glycol 400 stearate, polyethylene glycol 2000 stearate, especially ethylene oxide/propylene oxide block polymers of the type Pluronics~ (BWC) or Synperonic~ (ICI).
In a special embodiment tablets may also comprise excipients that are customary for the preparation of effervescent tablets, that is to say, in each case at least one excipient capable of releasing COZ and at least one excipient capable of inducing the release of C02.
An excipient capable of releasing C02 is, e.g., a pharmaceutically acceptable mono- or di-basic salt of carbonic acid, e.g. sodium or potassium carbonate, especially sodium hydrogen carbonate.
An excipient that induces the release of C02 is, e.g., a pharmaceutically acceptable acid that is in solid form and can be formulated into tablets with the active ingredient, the ion exchange resin and other excipients without the evolution of gas. A suitable acid is, e.g., tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, ascorbic acid or rnaleic acid. Citric acid is preferred.
The preparation of granules with the ion exchange resin defined hereinbefore is carried out in a mariner known ~ se especially by wet granulation methods.
Such processes proceed continuously, e.g. by means of simultaneous spraying with granulating solution of the mass to be granulated and drying, e.g. in a drum granulator, in granulating vessels, on dish granulators, in a fluid bed, by spray-drying or spray-solidifying, or proceed discontinuously, as, for example, in a fluidised bed, a batch mixer or a spray-drying drum.
Processes that can be carried out discontinuously are preferred, the mass to be granulated first of all forming a moist aggregate with the granulating solution fed in and the aggregate then being comminuted to form granules of the desired particle size using known - 2~~~~~
extrusion and spheronisation processes. Suitable extruders and spheronisers are, e.g.
apparatus produced by Wyss & Probst, Werner & Pfleiderer, HKD, Loser, Fuji, Nica, Caleva inter alia.
The mass to be granulated consists of comminuted, preferably ground, ion exchanger defined hereinbefore, preferably having a mean particle size of less than 400 p.m (more than 90 %), and the excipients mentioned hereinbefore, e.g. pulverulent fillers, such as microcxystalline cellulose of the AVICEL type. AVICEL PH 102 is especially suitable.
Depending on the process employed, the mass to be granulated can be premixed or can be obtained by admixing APD-Na2 with the ion exchange resin and with one or more excipients, or by admixing the excipients with the active ingredient.
The compression of the granules to form tablet cores can be carried out in conventional tabletting machines, preferably eccentric presses and rotary presses, especially EKO-Korsch eccentric tabletting machines, at an operating pressure of about 10 kN
or more.
Drag~es are produced e.g. by coating tablet cores with a film or coating layer of the partic-ular thickness required using the known fiuidised bed process, in confectioning vessels or according to coacervation processes.
The coating agent is, for example, dissolved or suspended in water in the desired propor-tion. Where appropriate, excipients such as polyethylene glycol are added. The solution or dispersion is sprayed onto the drag~e or tablet cores with other excipients, e.g. talc or silicon dioxide, e.g. SYLOID 244 FP, e.g. using known processes, such as fluidised bed spray-coating, e.g. in systems produced by Aeromatic, Glatt, Wurster or Hiittlin (ball coaters) or in a vessel according to the processes known by the names Aecela Cota.
Capsules are preferably dry-filled capsules made of gelatin, especially hard gelatin, which are prepared where appropriate with the addition of glycerol or sorbitol, are dissolved without time delay by the action of gastric juice and release components a) and b).
Capsules may comprise components a) and b) in the form of a mixture or in the form of granules. Other excipients and fillers, such as lactose, starch, and glidants such as starch or magnesium stearate, may be admixed. Soft capsules may, in addition, contain liquids, such as lecithin, fats, oils, paraffin oil or liquid polyethylene glycol. Dry-filled capsules size 0-4, preferably 0-2, are suitable, depending on the dose. Commercial products produced by Eli Lilly, Elanco, Capsugel or Scherer are suitable.
_g_ In a specific embodiment, the capsules may contain pellets, which are obtainable in accordance with the granulating processes described hereinbefore by subjecting the still moist mass to be granulated to extrusion or spheronisation processes to obtain regularly shaped, pxeferably spheroidal, granules in the form of pellets. A mean particle size of about O.S to 1.25 mm is preferred.
~ _- . Sachets are receptacles, for example bags made of polyethylene, lined paper or ..
aluminium, that contain the components a) and b), e.g. lecithin. The mixture can be removed directly after opening the sachet and administered orally, e.g. mixed with water.
Components a) and b) can also be contained in the form of granules or pellets in the said capsules and sachets.
The solid dosage forms described hereinbefore can be of different shapes, e.g.
of a round, oval, oblong or cylindrical shape, and of different sizes depending on the amount of active ingredient they contain. They may furthermore be transparent, colourless or coloured and, if desired, inscribed to give the products an individual appearance and allow immediate recognition. The use of dyestuffs can serve both to enhance the appearance and to charac-terise the preparation.
Liquid dosage forms are e.g. syrups, which are prepared by conventional mixing process such as those described in Hagers Handbuch der Pharmazeutischen Praxis, Springer Verlag, volume VII, part A, pages 640-644, or in Remington's Pharmaceutical Sciences, Mack 1985, pages 1500-1503. An aqueous suspension of the ion exchange resin with the ground active ingredient is first of all produced, and excipients, such as the mentioned wetting agents, viscosity-increasing substances (thickeners), preservatives, antioxidants, dyestuffs, flavour enhancers (flavourings), sugars and sweeteners are added to that suspension. Particles of ion exchange resins of a suitable size, e.g. larger than 1 pm and smaller than 100 pm, can, if desired, be produced by grinding.
Conventional methods indicated in standard works such as Halters Handbuch der Pharma-zeutischen Fraxis or Remington's Pharmaceutical Sciences can be used to produce oral liquid dosage forms, such as i.irops, suspensions, emulsions etc..
The pharmaceutical compositions according to the present invention are, on account of the advantageously low dose, distinguished by especially good gastrointestinal tolerance, especially of the active ingredient disodium pamidronate.
The dosage forms mentioned hereinbefore are suitable for the treatment of diseases that may be associated with disorders of calcium metabolism, for example inflammatory processes in 5 joints, degenerative processes in articular cartilages, osteoporosis, periodontitis, hyperparathyroidism, and for the treatment of calcium deposits in blood vessels or on prosthetic implants. Also favourably influenced are diseases in which an anomalous deposit of sparingly soluble 10 calcium salts is to be observed, such as those of the arthritis type, e.g. Bechterew's disease, neuritis, bursitis, periodontitis and tendinitis, fibrodysplasia, osteoarthrosis or arteriosclerosis, as well as diseases in which an anomalous dissolution of hard body tissue is prominent, such as hereditary hypophosphatasia, degenerative processes in articular cartilages, osteoporosis of various kinds, Paget's disease and osteodystrophia fibrosa, as well as osteolytic processes induced by tumours and also hypercalcaemia.
The pharmaceutical compositions described herein may be used in alleviating disorders of one or both of calcium and phosphate metabolism.
The present invention therefore also relates to the use of pharmaceutical solid dosage forms in a therapeutic or prophylactic method for the human or animal body.
The following Examples illustrate the invention.
Disodium pamidronate is abbreviated to APD-Na2.
l0a Example 1 Formulation for film-coated dragees. The amounts quoted are per unit dose form.
Film-coated drag~e core APD-Naa (active ingredient) 75.0 mg DUOLITE C 467 cationic ion exchange resin 425.0 mg microcrystalline cellulose A VICEL PH 102 75.0 mg cottonseed oil hydr. CUTINATM 15.0 mg 59 0 . 0 mg Protective f lm-coating TM
METHOCEL cellulose HPMC 603 10.0 mg talc TM 9.5 mg CREMOPHOR PH 40 0.5 mg Film-coated dragee having protective film-coating 610.0 mg Preparation: The cationic ion exchange.resin is.ground to an average particle size of pm in an air jet mill. 425 g of ion exchange resin are mixed with 75 g of active ingredient and 75 g of microcrystalline cellulose for ten minutes in a planet mixer (Knedwood), 15 g of cottonseed oil are added, and the batch is comminuted through a 0.5 mm sieve and mixed again for 5 minutes. The mixture is compressed in an eccentric press EKO (punch size 11.5 mm). The cores are coated in a fluidised bed (Strea 1) with the protective film- coating of the composition indicated.
Example 2 Formulation for capsule filling (liquid). The amounts quoted are per unit dose form.
APD-Na2 (active ingredient) 75.0 mg DUOLITE C 467 cationic ion exchange resin 275.0 mg groundnut oil 120.0 mg beeswax 30.0 mg capsule filling mass 500.0 mg Hard gelatin capsule size 0 Preparation: 275 g of cationic ion exchange resin are ground as indicated in Example 1 and mixed with 75 g of active ingredient and 120 g of groundnut oil. This mixture is intro-duced in a liquid-filling station (Hiiflinger & Karg) into size 0 hard gelatin capsules.
Example 3 Formulation for pellets. The amounts quoted are per unit dose form.
Pellet cores APD-Na2 (active ingredient) 75.0 mg DUOLITE C 467 cationic ion exchange resin 275.0 mg microcrystalline cellulose AVICEL PH 102 48.0 mg 398.0 mg Protective, film-coating cellulose ether METHOCEL HPM 603 5.0 mg talc 4.75 mg CREMOPHOR PH 40 0.25 mg Basic pellet having protective film-coating 408.0 mg Preparation: 275 g of cationic ion exchange resin are ground as indicated in Example 1 and mixed with 75 g of active ingredient and 48 g of microcrystalline cellulose. The mixture is moistened with demineralised water, extruded and pelleted. The pellets are coated in a fluidised bed (Strea 1) with the protective film-coating of the composition indicated.
Example 4 Formulation for film-coated drag~es. The amounts are given per unit dose form.
1-Hydroxy-3-(N-methyl-N-n-pentylamino)-propane-1,1-diphosphonic acid 20,0 mg DUOLITE C 467 cation.ion exchange resin 200,0 mg SOFTISAN TM 50,0 mg MIGLYOL"~ 200,0 mg capsule filling mass 470,0 mg Hard gelatin capsule size 0 20,0 mg active ingredient and 200 g DUOLITE are ground in an air suspension mill and mixed with the given additives. The paste is filled into size 0 hard gelatine capsules.M
Example 5 Formulation for film-coated drag~es. The amounts are given per unit dose form.
2~~~~~.~
1-Hydroxy-2-(3-pyridyl)-ethane-1,1-diphosphonic acid 20,0 mg DUOLITE C 467 cation. ion exchange resin 150,0 mg soy bean lecithin 10,0 mg sesame oil 250,0 mg capsule filling mass 430, mg Hard gelatin capsule size 0 g soy bean lecithin are dissolved in 250 g sesame oil. 150 g DUOLITE are dispersed therein and wet ground in a sand mill. The calculated amount of active ingredient is added and the mixture is introduced into a liquid-filling station (Hdflinger & Karg) into size 0 hard gelatine capsules.
According to another aspect of the present invention, there is provided a pharmaceutical composition for the oral administration of methanediphosphonic acid derivatives, comprising a) a methanediphosphonic acid derivative of formula:
~ 03H2 R1- ~ -R2 (I ), wherein one of Rl and RZ is hydrogen or hydroxy and the other is amino-C1_4alkyl, CZ_salkyleneamino-C1_4alkyl, N-mono- or N, N-di-C1_8alkylamino-Cz_4alkyl, C5_~cycloalkylamino, heteroaryl-C1_4alkyl or N-C1_4alkyl-N-phenylthio-C1_4alkylamino-C1_4alkyl, or a pharmaceutically acceptable salt of the derivative, and b) particles of a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group.
In an especially preferred embodiment, the pharmaceutical composition comprises disodium pamidronate in a dose per unit dose form of 50-10o mg, especially 50-80 mg, in admixture with the cationic ion exchange resin Duolite~
( Trade Mark of Rohm & Haas ) C 4 6 7 .
The pharmaceutical composition is preferably administrable in the form of tablets, dragees or capsules and is distinguished by an especially marked reduction in the level of calcium in the plasma. In-vivo findings using rats have shown that, with the new dosage form, the capacity for absorption of the active ingredient when methanediphosphonic acid derivatives are administered orally in an oily or aqueous suspension in admixture with an excess of ion exchange resin based on the active ingredient in a ratio by weight of 1:10 is more than six times greater compared with an orally administered aqueous suspension of the active ingredient. The effective dose ascertained from in-vivo findings is approximately 8 mg/kg (p.o.).
The terms and definitions used hereinbefore and hereinafter preferably have the following meanings within the scope of the description of the invention:
The term "pharmaceutical composition" defines mixtures of methanediphosphonic acid derivatives (I) with resin particles of the cationic ion exchanger defined hereinbefore and, where appropriate, customary pharmaceutical excipients, that can be processed into oral dosage forms, such as tablets, capsules or dragees.
The present invention also relates to a process for the preparation of the pharmaceutical composition, which comprises mixing together a) at least one methanediphosphonic acid derivative (I) and 4a b) resin particles of a cationic macroporous ion exchanger based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group and, where appropriate, c) further pharmaceutically acceptable excipients, and further processing the mixture to produce an oral dosage form.
According to another aspect of the present invention, there is provided a process for the preparation of a pharmaceutical composition for the oral administration of a methanediphosphonic acid derivative, which comprises mixing together a) a methanediphosphonic acid derivative of formula I, as described herein, b) resin particles of a cationic ion exchanger based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group, and further processing the mixture to produce an oral dosage form.
In a compound (I), amino-C1_4alkyl is preferably 2-amino-1-ethyl or 3-amino-1-propyl.
CZ_6Alkyleneamino-Cl_4alkyl is preferably 2- (a,w-C2_4alkyleneamino)-1-ethyl, e.g. 2-(1,4-butyleneamino)-1-ethyl.
N-Mono- or N,N-di-C1_ealkylamino-Ca_4alkyl is preferably 2- (N-C1_4alkyl-N-C4_ealkylamino) -1-ethyl, e.g. 2-(N-methyl-N-n-pentylamino)-1-ethyl.
CS_.,Cycloalkylamino is preferably cycloheptyl- or cyclohexyl-amino.
4b Heteroaryl-Cl_4alkyl is preferably azaaryl-C1_4alkyl having five or six ring members, e.g. 2-, 3-, or 4-pyridylmethyl.
N-Cl_4Alky1-N-phenylthio-Cl_4alkylamino-C1_4alkyl is e.g. 2-[N-methyl-N-(2-phenylthio-1-ethyl)-amino]-1-ethyl.
Salts of methanediphosphonic acid derivatives are especially pharmaceutically acceptable salts formed with amines, but are especially alkali metal salts, e.g. sodium or potassium salts.
The following compounds are especially preferred:
3-Amino-1-hydroxypropane-1,1-diphosphonic acid, 4-amino-1-hydroxy-n-butane-1,1-diphosphonic acid, 3-(1,4-butyleneamino)-1-hydroxypropane-1,I-diphosphonic acid, 1-hydroxy-3-(N-methyl-N-n-pentylamino)-propane-1,1-diphosphonic acid, 1-cyclohexylaminomethane-1,1-diphosphonic acid, 1-hydroxy-2-(3-pyridyl)-ethane-1,1-diphosphonic acid, 1-hydroxy-3-[N-methyl-N-(2-phenylthio-1-ethyl)-amino]-propane-1,1-diphosphonic acid and salts of those compounds.
The especially preferred component a) disodium 3-amino-1-hydroxypropane-1,1-diphosphonate (disodium pamidronate) in the pharmaceutical composition is preferably in the form of the crystalline hydrate, preferably the pentahydrate, the preparation and character--s-istic data of which are described in published European Patent Application 177 443.
An advantageous oral dose has about 20-150 mg, especially about 50-100 mg, more especially about 50-80 mg of active ingredient per unit dose form.
Component b) consists of resin particles of a cationic, microporous or, preferably, macro-porous ion exchanger based on a styrenefdivinylbenzene copolymer having an exchange-able aminophosphonate. group. The matrix consists of polymerised styrene swellable in the aqueous phase with divinylbenzene as crosslinking agent and functional aminophos-phonate groups that are charged with exchangeable canons, especially sodium ions.1n the commercial product Duolite~ C 467, the aminophosphonate group consists of the phos-phonic acid methylaminomethyl group (-CH2-NH-CH2-P03H2) in the form of the canon-exchangeable mono- or di-sadium salt (-CH2-NH-CHZ-P03HNa or -CHZ-NH-CH2-P03Na2). The characteristic data of the commercial product Duolite~ C 467 are as follows:
external appearance beige-coloured beads ionic form Nay exchange capacity 1 equivalent per litre (Na+ form) 1.4 equivalents per litre (H~ form) specific weight 1.12 (Na+ form) suspension 740 g/1 particle size ~ 0.3-1 mm swelling capacity 35 % (H+ form ~ Na+ form) The characteristic data were taken from Product Data Sheet DTS 0092 A
(published in June 1991) of Rohm & Haas.
The average particle size of the resin particles is about 1-200 p.m, especially 10-100 p.m.
The crosslinking is about 2-8 °lo, preferably 2-4 °Jo.
In a special embodiment, the mixing ratio of methanediphosphonic acid derivative (I) to resin particles of the ion exchanger is about 1:1 to 1:100, preferably about l:l to 1:20, especially 1:1 to 1:10.
Component c) consists of pharmaceutically acceptable excipients that can be used for the preparation of oral dosage forms, e.g. solid unit dose forms, such as tablets, dragdes, capsules or sachets, but also of liquid dosage forms, such as syrups, drops, suspensions, emulsions etc..
Tablets are obtained by the direct compression of components a) and b) with customary excipients> such as lactose, mannitol, microcrystalline cellulose or talc, or preferably by the compression of granules.
Granules are also solid medicament preparations that comprise the methanediphosphonic acid derivative (I) and the ion exchange resin defined hereinbefore and such excipients as are customary in the pharmaceutical technology of tabletting processes. The granules according to the present invention can also themselves be used as oral dosage forms when introduced, fox example, into capsules or sachets, but they are preferably further processed to form tablets.
Suitable excipients for the preparation of granules are, e.g., pulverulent fillers with flow-regulating properties, e.g. talc, silicon dioxide, e.g. synthetic amorphous dehydrated silicic acid of the type Syloid~(Grace), e.g. SYLOID 244 FP, microcrystalline cellulose, e.g. of the type Avicel~ (FMC Corp.), e.g. the types AVICEL PH 101, 102, 105, RC 5$1 or RC 591, Emcocelp (Mendell Corp.) or Elcema~ (Degussa), carbohydrates such as sugars, sugar alcohols, starch or starch derivatives, e.g. lactose, dextrose, saccharose, glucose, sorbitol; mannitol, xylitol, potato starch, corn starch, rice starch or wheat starch or amylo-pectin, tricalcium phosphate, calcium hydrogen phosphate or magnesium trisilicate, binders such as gelatin, tragacanth, agar, alginic acid, cellulose ethers, e.g. methylcellu-lose, carboxymethylcellulose or hydraxypropylmethylcellulose, polyethylene glycols or ethylene oxide homopolymers, especially having a degree of polymerisation of about 2.0 x 103 - 1.0 x 105 and an approximate molecular weight of about 1.0 x 105 -5.0 x 106, e.g. excipients known by the name of Polyox~ (Union Carbide), polyvinylpyrrolidone or povidones> especially having a mean molecular weight of about 10 000-360 000, polyvinyl alcohol having a degree of hydrolysis of about 95-99 % and a degree of polymerisation of about 500-2500, and agar or gelatin, surface-active substances, e.g. anionic surfactants of the alkyl sulfate type, e.g. sodium, potassium or magnesium n-dodecyl sulfate, n-tetra-decyl sulfate, n-hexadecyl sulfate or n-octadecyl sulfate, of the allcyl ether sulfate type, e.g. sodium, potassium or magnesium n-dodecyloxyethyl sulfate, n-tetradecyloxyethyl sulfate, n-hexadecyloxyethyl sulfate or n-octadecyloxyethyl sulfate, or of the alkane-sulfonate type, e.g. sodium, potassium or magnesium n-dodecanesulfonate, n-tetradecane--sulfonate, n-hexadecanesulfonate or n-octadecanesulfonate, non-ionic surfactants of the fatty acid polyhydroxyalcohol ester type, such as sorbitan mono-laurate, -oleate, -stearate or -palmitate, sorbitan tristearate or trioleate, polyoxyethylene adducts of fatty acid poly-hydroxyalcohol esters, such as polyoxyethylene sorbitan mono-laurate, -oleate, -stearate, -palmitate, tristearate or trioleate, polyethylene glycol fatty acid esters, such as poly-oxyethyl stearate, polyethylene glycol 400 stearate, polyethylene glycol 2000 stearate, especially ethylene oxide/propylene oxide block polymers of the type Pluronics~ (BWC) or Synperonic~ (ICI).
In a special embodiment tablets may also comprise excipients that are customary for the preparation of effervescent tablets, that is to say, in each case at least one excipient capable of releasing COZ and at least one excipient capable of inducing the release of C02.
An excipient capable of releasing C02 is, e.g., a pharmaceutically acceptable mono- or di-basic salt of carbonic acid, e.g. sodium or potassium carbonate, especially sodium hydrogen carbonate.
An excipient that induces the release of C02 is, e.g., a pharmaceutically acceptable acid that is in solid form and can be formulated into tablets with the active ingredient, the ion exchange resin and other excipients without the evolution of gas. A suitable acid is, e.g., tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, ascorbic acid or rnaleic acid. Citric acid is preferred.
The preparation of granules with the ion exchange resin defined hereinbefore is carried out in a mariner known ~ se especially by wet granulation methods.
Such processes proceed continuously, e.g. by means of simultaneous spraying with granulating solution of the mass to be granulated and drying, e.g. in a drum granulator, in granulating vessels, on dish granulators, in a fluid bed, by spray-drying or spray-solidifying, or proceed discontinuously, as, for example, in a fluidised bed, a batch mixer or a spray-drying drum.
Processes that can be carried out discontinuously are preferred, the mass to be granulated first of all forming a moist aggregate with the granulating solution fed in and the aggregate then being comminuted to form granules of the desired particle size using known - 2~~~~~
extrusion and spheronisation processes. Suitable extruders and spheronisers are, e.g.
apparatus produced by Wyss & Probst, Werner & Pfleiderer, HKD, Loser, Fuji, Nica, Caleva inter alia.
The mass to be granulated consists of comminuted, preferably ground, ion exchanger defined hereinbefore, preferably having a mean particle size of less than 400 p.m (more than 90 %), and the excipients mentioned hereinbefore, e.g. pulverulent fillers, such as microcxystalline cellulose of the AVICEL type. AVICEL PH 102 is especially suitable.
Depending on the process employed, the mass to be granulated can be premixed or can be obtained by admixing APD-Na2 with the ion exchange resin and with one or more excipients, or by admixing the excipients with the active ingredient.
The compression of the granules to form tablet cores can be carried out in conventional tabletting machines, preferably eccentric presses and rotary presses, especially EKO-Korsch eccentric tabletting machines, at an operating pressure of about 10 kN
or more.
Drag~es are produced e.g. by coating tablet cores with a film or coating layer of the partic-ular thickness required using the known fiuidised bed process, in confectioning vessels or according to coacervation processes.
The coating agent is, for example, dissolved or suspended in water in the desired propor-tion. Where appropriate, excipients such as polyethylene glycol are added. The solution or dispersion is sprayed onto the drag~e or tablet cores with other excipients, e.g. talc or silicon dioxide, e.g. SYLOID 244 FP, e.g. using known processes, such as fluidised bed spray-coating, e.g. in systems produced by Aeromatic, Glatt, Wurster or Hiittlin (ball coaters) or in a vessel according to the processes known by the names Aecela Cota.
Capsules are preferably dry-filled capsules made of gelatin, especially hard gelatin, which are prepared where appropriate with the addition of glycerol or sorbitol, are dissolved without time delay by the action of gastric juice and release components a) and b).
Capsules may comprise components a) and b) in the form of a mixture or in the form of granules. Other excipients and fillers, such as lactose, starch, and glidants such as starch or magnesium stearate, may be admixed. Soft capsules may, in addition, contain liquids, such as lecithin, fats, oils, paraffin oil or liquid polyethylene glycol. Dry-filled capsules size 0-4, preferably 0-2, are suitable, depending on the dose. Commercial products produced by Eli Lilly, Elanco, Capsugel or Scherer are suitable.
_g_ In a specific embodiment, the capsules may contain pellets, which are obtainable in accordance with the granulating processes described hereinbefore by subjecting the still moist mass to be granulated to extrusion or spheronisation processes to obtain regularly shaped, pxeferably spheroidal, granules in the form of pellets. A mean particle size of about O.S to 1.25 mm is preferred.
~ _- . Sachets are receptacles, for example bags made of polyethylene, lined paper or ..
aluminium, that contain the components a) and b), e.g. lecithin. The mixture can be removed directly after opening the sachet and administered orally, e.g. mixed with water.
Components a) and b) can also be contained in the form of granules or pellets in the said capsules and sachets.
The solid dosage forms described hereinbefore can be of different shapes, e.g.
of a round, oval, oblong or cylindrical shape, and of different sizes depending on the amount of active ingredient they contain. They may furthermore be transparent, colourless or coloured and, if desired, inscribed to give the products an individual appearance and allow immediate recognition. The use of dyestuffs can serve both to enhance the appearance and to charac-terise the preparation.
Liquid dosage forms are e.g. syrups, which are prepared by conventional mixing process such as those described in Hagers Handbuch der Pharmazeutischen Praxis, Springer Verlag, volume VII, part A, pages 640-644, or in Remington's Pharmaceutical Sciences, Mack 1985, pages 1500-1503. An aqueous suspension of the ion exchange resin with the ground active ingredient is first of all produced, and excipients, such as the mentioned wetting agents, viscosity-increasing substances (thickeners), preservatives, antioxidants, dyestuffs, flavour enhancers (flavourings), sugars and sweeteners are added to that suspension. Particles of ion exchange resins of a suitable size, e.g. larger than 1 pm and smaller than 100 pm, can, if desired, be produced by grinding.
Conventional methods indicated in standard works such as Halters Handbuch der Pharma-zeutischen Fraxis or Remington's Pharmaceutical Sciences can be used to produce oral liquid dosage forms, such as i.irops, suspensions, emulsions etc..
The pharmaceutical compositions according to the present invention are, on account of the advantageously low dose, distinguished by especially good gastrointestinal tolerance, especially of the active ingredient disodium pamidronate.
The dosage forms mentioned hereinbefore are suitable for the treatment of diseases that may be associated with disorders of calcium metabolism, for example inflammatory processes in 5 joints, degenerative processes in articular cartilages, osteoporosis, periodontitis, hyperparathyroidism, and for the treatment of calcium deposits in blood vessels or on prosthetic implants. Also favourably influenced are diseases in which an anomalous deposit of sparingly soluble 10 calcium salts is to be observed, such as those of the arthritis type, e.g. Bechterew's disease, neuritis, bursitis, periodontitis and tendinitis, fibrodysplasia, osteoarthrosis or arteriosclerosis, as well as diseases in which an anomalous dissolution of hard body tissue is prominent, such as hereditary hypophosphatasia, degenerative processes in articular cartilages, osteoporosis of various kinds, Paget's disease and osteodystrophia fibrosa, as well as osteolytic processes induced by tumours and also hypercalcaemia.
The pharmaceutical compositions described herein may be used in alleviating disorders of one or both of calcium and phosphate metabolism.
The present invention therefore also relates to the use of pharmaceutical solid dosage forms in a therapeutic or prophylactic method for the human or animal body.
The following Examples illustrate the invention.
Disodium pamidronate is abbreviated to APD-Na2.
l0a Example 1 Formulation for film-coated dragees. The amounts quoted are per unit dose form.
Film-coated drag~e core APD-Naa (active ingredient) 75.0 mg DUOLITE C 467 cationic ion exchange resin 425.0 mg microcrystalline cellulose A VICEL PH 102 75.0 mg cottonseed oil hydr. CUTINATM 15.0 mg 59 0 . 0 mg Protective f lm-coating TM
METHOCEL cellulose HPMC 603 10.0 mg talc TM 9.5 mg CREMOPHOR PH 40 0.5 mg Film-coated dragee having protective film-coating 610.0 mg Preparation: The cationic ion exchange.resin is.ground to an average particle size of pm in an air jet mill. 425 g of ion exchange resin are mixed with 75 g of active ingredient and 75 g of microcrystalline cellulose for ten minutes in a planet mixer (Knedwood), 15 g of cottonseed oil are added, and the batch is comminuted through a 0.5 mm sieve and mixed again for 5 minutes. The mixture is compressed in an eccentric press EKO (punch size 11.5 mm). The cores are coated in a fluidised bed (Strea 1) with the protective film- coating of the composition indicated.
Example 2 Formulation for capsule filling (liquid). The amounts quoted are per unit dose form.
APD-Na2 (active ingredient) 75.0 mg DUOLITE C 467 cationic ion exchange resin 275.0 mg groundnut oil 120.0 mg beeswax 30.0 mg capsule filling mass 500.0 mg Hard gelatin capsule size 0 Preparation: 275 g of cationic ion exchange resin are ground as indicated in Example 1 and mixed with 75 g of active ingredient and 120 g of groundnut oil. This mixture is intro-duced in a liquid-filling station (Hiiflinger & Karg) into size 0 hard gelatin capsules.
Example 3 Formulation for pellets. The amounts quoted are per unit dose form.
Pellet cores APD-Na2 (active ingredient) 75.0 mg DUOLITE C 467 cationic ion exchange resin 275.0 mg microcrystalline cellulose AVICEL PH 102 48.0 mg 398.0 mg Protective, film-coating cellulose ether METHOCEL HPM 603 5.0 mg talc 4.75 mg CREMOPHOR PH 40 0.25 mg Basic pellet having protective film-coating 408.0 mg Preparation: 275 g of cationic ion exchange resin are ground as indicated in Example 1 and mixed with 75 g of active ingredient and 48 g of microcrystalline cellulose. The mixture is moistened with demineralised water, extruded and pelleted. The pellets are coated in a fluidised bed (Strea 1) with the protective film-coating of the composition indicated.
Example 4 Formulation for film-coated drag~es. The amounts are given per unit dose form.
1-Hydroxy-3-(N-methyl-N-n-pentylamino)-propane-1,1-diphosphonic acid 20,0 mg DUOLITE C 467 cation.ion exchange resin 200,0 mg SOFTISAN TM 50,0 mg MIGLYOL"~ 200,0 mg capsule filling mass 470,0 mg Hard gelatin capsule size 0 20,0 mg active ingredient and 200 g DUOLITE are ground in an air suspension mill and mixed with the given additives. The paste is filled into size 0 hard gelatine capsules.M
Example 5 Formulation for film-coated drag~es. The amounts are given per unit dose form.
2~~~~~.~
1-Hydroxy-2-(3-pyridyl)-ethane-1,1-diphosphonic acid 20,0 mg DUOLITE C 467 cation. ion exchange resin 150,0 mg soy bean lecithin 10,0 mg sesame oil 250,0 mg capsule filling mass 430, mg Hard gelatin capsule size 0 g soy bean lecithin are dissolved in 250 g sesame oil. 150 g DUOLITE are dispersed therein and wet ground in a sand mill. The calculated amount of active ingredient is added and the mixture is introduced into a liquid-filling station (Hdflinger & Karg) into size 0 hard gelatine capsules.
Claims (18)
1. A pharmaceutical composition for the oral administration of methanediphosphonic acid derivatives, comprising a) a methanediphosphonic acid derivative of formula:
wherein one of R1 and R2 is hydrogen or hydroxy and the other is amino-C1-4alkyl, C2-6alkyleneamino-C1-4alkyl, N-mono- or N,N-di-C1-8alkylamino-C2-4alkyl, C5-7cycloalkylamino, heteroaryl-C1-4alkyl or N-C1-4alkyl-N-phenylthio-C1-4alkylamino-C1-4alkyl, or a pharmaceutically acceptable salt of the derivative, and b) particles of a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group.
wherein one of R1 and R2 is hydrogen or hydroxy and the other is amino-C1-4alkyl, C2-6alkyleneamino-C1-4alkyl, N-mono- or N,N-di-C1-8alkylamino-C2-4alkyl, C5-7cycloalkylamino, heteroaryl-C1-4alkyl or N-C1-4alkyl-N-phenylthio-C1-4alkylamino-C1-4alkyl, or a pharmaceutically acceptable salt of the derivative, and b) particles of a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group.
2. A pharmaceutical composition according to claim 1, further comprising one or more pharmaceutically acceptable excipient.
3. A pharmaceutical composition according to claim 1 or 2, wherein, in the methanediphosphonic acid derivative of formula I, one of R1 and R2 is hydrogen or hydroxy and the other is 2-amino-1-ethyl, 3-amino-1-propyl, 2-(1,4-butylene-amino)-1-ethyl, 2-(N-methyl-N-n-pentylamino)-1-ethyl, cycloheptyl- or cyclohexyl-amino, 2-, 3- or 4-pyridylmethyl or [N-methyl-N-(2-phenylthio-1-ethyl)-amino]-1-ethyl.
4. A pharmaceutical composition according to claim 1 or 2, wherein the methanediphosphonic acid derivative is selected from 3-amino-1-hydroxy-propane-1, 1-diphosphonic acid, 4-amino-1-hydroxy-n-butane-1, 1-diphosphonic acid, 3-(1,4-butyleneamino)-1-hydroxypropane-1, 1-diphosphonic acid, 1-hydroxy-3-(N-methyl-N-n-pentylamino)-propane-1, 1-diphosphonic acid, 1-cyclohexylaminomethane-1,1-diphosphonic acid, 1-hydroxy-2-(3-pyridyl)-ethane-1, 1-diphosphonic acid, 1-hydroxy-3-[N-methyl-N-(2-phenylthio-1-ethyl)-amino]-propane-1,1-diphosphonic acid and a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition according to claim 1 or 2, wherein the methanediphosphonic acid derivative is crystalline pentahydrate of disodium pamidronate.
6. A pharmaceutical composition according to claim 1 or 2, wherein the methanediphosphonic acid derivative is crystalline pentahydrate of disodium pamidronate in a dose of 50-100 mg per unit dose form.
7. A pharmaceutical composition according to claim 1 or 2, wherein the methanediphosphonic acid derivative is crystalline pentahydrate of disodium pamidronate in a dose of 50-80 mg per unit dose form.
8. A pharmaceutical composition according to any one of claims 1 to 7, wherein the mixing ratio of the methanediphosphonic acid derivative to the ion exchange resin particles is from 1:1 to 1:100.
9. A pharmaceutical composition according to any one of claims 1 to 7, wherein the mixing ratio of the methanediphosphonic acid derivative to the ion exchange resin particles is from 1:1 to 1:20.
10. A pharmaceutical composition according to any one of claims 1 to 7, wherein the mixing ratio of the methanediphosphonic acid derivative to the ion exchange resin particles is from 1:1 to 1:10.
11. A pharmaceutical composition according to any one of claims 1 to 10, wherein the ion exchange resin particles of the exchangeable aminophosphonate group comprises an exchangeable phosphonic acid methylaminomethyl group in salt form.
12. A pharmaceutical composition according to claim 11, wherein the exchangeable phosphonic acid methylaminomethyl group is in the form of the mono- or di-sodium salt.
13. A pharmaceutical composition according to any one of claims 1 to 12, in the form of tablets, capsules, dragées or pellets.
14. A process for the preparation of a pharmaceutical composition for the oral administration of a methanediphosphonic acid derivative, which comprises mixing together a) a methanediphosphonic acid derivative of formula I, as defined in claim 1, b) resin particles of a cationic ion exchanger based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group, and further processing the mixture to produce an oral dosage form.
15. A process according to claim 14, further comprising mixing one or more pharmaceutically acceptable excipients with components a) and b) prior to the step of further processing the mixture to produce the oral dosage form.
16. A process according to claim 15, wherein the methanediphosphonic acid derivative of formula I is crystalline disodium pamidronate pentahydrate, and the oral dosage form is selected from tablets, capsules, dragées and pellets.
17. A pharmaceutical composition according to any one of claims 1 to 13 for use in treating a human or animal body.
18. A pharmaceutical composition according to claim 17 for use in alleviating disorders of one or both of calcium and phosphate metabolism.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1247/92-5 | 1992-04-15 | ||
| CH124792 | 1992-04-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2093946A1 CA2093946A1 (en) | 1993-10-16 |
| CA2093946C true CA2093946C (en) | 2005-07-05 |
Family
ID=4205927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002093946A Expired - Fee Related CA2093946C (en) | 1992-04-15 | 1993-04-13 | Methanediphosphonic acid formulations with ion exchangers |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5344825A (en) |
| EP (1) | EP0566535B1 (en) |
| JP (1) | JP3970941B2 (en) |
| KR (1) | KR100307786B1 (en) |
| AT (1) | ATE183096T1 (en) |
| AU (1) | AU665814B2 (en) |
| CA (1) | CA2093946C (en) |
| DE (1) | DE59309727D1 (en) |
| DK (1) | DK0566535T3 (en) |
| ES (1) | ES2137241T3 (en) |
| FI (1) | FI110920B (en) |
| GR (1) | GR3031645T3 (en) |
| HU (1) | HU219022B (en) |
| IL (1) | IL105382A (en) |
| MX (1) | MX9302151A (en) |
| NO (1) | NO306978B1 (en) |
| NZ (1) | NZ247398A (en) |
| PH (1) | PH30733A (en) |
| TW (1) | TW237386B (en) |
| ZA (1) | ZA932613B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406714B1 (en) | 1992-12-02 | 2002-06-18 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids |
| US5591730A (en) * | 1993-10-12 | 1997-01-07 | The Regents Of The University Of California | Inhibition of urinary calculi growth |
| US20010007863A1 (en) * | 1998-06-18 | 2001-07-12 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
| TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
| DE19615812A1 (en) * | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmaceutical preparation containing diphosphonic acids for oral administration |
| DE19719680A1 (en) | 1997-05-09 | 1998-11-19 | Boehringer Mannheim Gmbh | Use of diphosphonic acids for the preventive treatment of long-term consequences of bladder enlargement or replacement |
| DE69826660T2 (en) * | 1997-06-11 | 2005-10-06 | The Procter & Gamble Company, Cincinnati | FILM-RELATED TABLET FOR IMPROVED COMPATIBILITY IN THE UPPER MAGIC DARMTRACT |
| FI104901B (en) | 1997-10-20 | 2000-04-28 | Leiras Oy | New methylene bisphosphonic acid derivatives |
| US6794536B1 (en) | 1998-12-10 | 2004-09-21 | Aesqen, Inc. | Method for preparation of disodium pamidronate |
| US6160165A (en) * | 1998-12-10 | 2000-12-12 | Aesgen, Inc. | Method for preparation of disodium pamidronate |
| SE9901272D0 (en) * | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| WO2002058708A1 (en) * | 2001-01-23 | 2002-08-01 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
| US6933127B2 (en) | 2001-07-05 | 2005-08-23 | Eucro European Contract Research Gmbh & Co. Kg | Substrate for PP2C |
| WO2003020242A1 (en) * | 2001-08-29 | 2003-03-13 | Srl Technologies, Inc. | Sustained release preparations |
| HUP0402267A3 (en) * | 2001-12-21 | 2007-05-29 | Procter & Gamble | Method for treatment of bone disorders |
| BR0308901A (en) * | 2002-05-10 | 2005-01-04 | Hoffmann La Roche | bisphosphonic acids for osteoporosis treatment and prevention |
| JP2004018524A (en) * | 2002-06-13 | 2004-01-22 | Eucro European Contract Research Gmbh & Co Kg | Method for treating arteriosclerosis |
| EP1396263A1 (en) * | 2002-08-09 | 2004-03-10 | Warner-Lambert Company | Film coating for tablets and caplets |
| US20040043072A1 (en) * | 2002-09-04 | 2004-03-04 | Will Joanne Patricia | Alleviation of upper gastrointestinal irritation |
| CN1649598B (en) * | 2002-12-20 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | High dose ibandronate formulation |
| US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
| JP4896480B2 (en) * | 2004-10-01 | 2012-03-14 | 第一三共ヘルスケア株式会社 | Particulate composition of anion exchange resin |
| GB201200868D0 (en) | 2012-01-19 | 2012-02-29 | Depuy Int Ltd | Bone filler composition |
| CA3077421A1 (en) * | 2017-10-02 | 2019-04-11 | Board Of Regents, The University Of Texas System | Inhalable composition of clofazimine and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2130794C3 (en) | 1971-06-22 | 1974-07-11 | Joh. A. Benckiser Gmbh, 6700 Ludwigshafen | Process for the preparation of l-hydroxy-S-aminopropane-ljl-diphosphonic acid |
| DE2405254C2 (en) | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 Düsseldorf | Use of 3-amino-1-hydroxypropane-1, 1-diphosphonic acid or its water-soluble salts for influencing calcium metabolic disorders in the human or animal body |
| JPS57177012A (en) * | 1981-04-23 | 1982-10-30 | Sumitomo Chem Co Ltd | Preparation of chelate resin |
| IT1201087B (en) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS |
| US4639338A (en) | 1984-08-06 | 1987-01-27 | Ciba-Geigy Corporation | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate |
| IL84494A (en) * | 1986-11-21 | 1992-08-18 | Ciba Geigy Ag | Heteroaryl substituted aminomethane-diphosphonic acids,their preparation and pharmaceutical compositions containing them |
| US5057505A (en) * | 1986-11-21 | 1991-10-15 | Ciba-Geigy Corporation | Substituted aminomethanediphosphonic acids and use in medicaments |
| DE3822650A1 (en) * | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
| US4996047A (en) * | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
| MX21452A (en) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | PHARMACEUTICAL PREPARATIONS THAT ARE TOPICALLY ADMINISTERED. |
| PH27186A (en) | 1989-09-07 | 1993-04-16 | Ciba Geigy Ag | Double-coated granules of disodium pamidronate |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
-
1993
- 1993-04-03 TW TW082102547A patent/TW237386B/zh not_active IP Right Cessation
- 1993-04-06 ES ES93810246T patent/ES2137241T3/en not_active Expired - Lifetime
- 1993-04-06 AT AT93810246T patent/ATE183096T1/en not_active IP Right Cessation
- 1993-04-06 DK DK93810246T patent/DK0566535T3/en active
- 1993-04-06 DE DE59309727T patent/DE59309727D1/en not_active Expired - Fee Related
- 1993-04-06 EP EP93810246A patent/EP0566535B1/en not_active Expired - Lifetime
- 1993-04-08 FI FI931633A patent/FI110920B/en active
- 1993-04-13 CA CA002093946A patent/CA2093946C/en not_active Expired - Fee Related
- 1993-04-14 ZA ZA932613A patent/ZA932613B/en unknown
- 1993-04-14 KR KR1019930006176A patent/KR100307786B1/en not_active IP Right Cessation
- 1993-04-14 IL IL105382A patent/IL105382A/en not_active IP Right Cessation
- 1993-04-14 NZ NZ247398A patent/NZ247398A/en not_active IP Right Cessation
- 1993-04-14 NO NO931367A patent/NO306978B1/en not_active IP Right Cessation
- 1993-04-14 HU HU9301088A patent/HU219022B/en not_active IP Right Cessation
- 1993-04-14 US US08/048,395 patent/US5344825A/en not_active Expired - Lifetime
- 1993-04-14 PH PH46038A patent/PH30733A/en unknown
- 1993-04-14 MX MX9302151A patent/MX9302151A/en not_active IP Right Cessation
- 1993-04-15 AU AU36961/93A patent/AU665814B2/en not_active Ceased
- 1993-04-15 JP JP08863193A patent/JP3970941B2/en not_active Expired - Fee Related
-
1999
- 1999-10-27 GR GR990402734T patent/GR3031645T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR100307786B1 (en) | 2001-11-30 |
| NO931367L (en) | 1993-10-18 |
| HUT63766A (en) | 1993-10-28 |
| DK0566535T3 (en) | 2000-03-06 |
| ES2137241T3 (en) | 1999-12-16 |
| NO306978B1 (en) | 2000-01-24 |
| EP0566535B1 (en) | 1999-08-11 |
| JPH069408A (en) | 1994-01-18 |
| MX9302151A (en) | 1993-10-01 |
| HU219022B (en) | 2001-04-28 |
| TW237386B (en) | 1995-01-01 |
| GR3031645T3 (en) | 2000-02-29 |
| AU3696193A (en) | 1993-10-21 |
| FI931633A0 (en) | 1993-04-08 |
| CA2093946A1 (en) | 1993-10-16 |
| ATE183096T1 (en) | 1999-08-15 |
| EP0566535A1 (en) | 1993-10-20 |
| IL105382A0 (en) | 1993-08-18 |
| US5344825A (en) | 1994-09-06 |
| PH30733A (en) | 1997-10-17 |
| FI110920B (en) | 2003-04-30 |
| IL105382A (en) | 1998-06-15 |
| KR940005268A (en) | 1994-03-21 |
| NZ247398A (en) | 1995-07-26 |
| HU9301088D0 (en) | 1993-06-28 |
| ZA932613B (en) | 1993-10-26 |
| FI931633A (en) | 1993-10-16 |
| AU665814B2 (en) | 1996-01-18 |
| JP3970941B2 (en) | 2007-09-05 |
| DE59309727D1 (en) | 1999-09-16 |
| NO931367D0 (en) | 1993-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2093946C (en) | Methanediphosphonic acid formulations with ion exchangers | |
| CA2024631C (en) | Double-coated granules of disodium pamidronate | |
| RU2193881C2 (en) | Pharmaceutical ibandronate-containing preparation for oral usage | |
| KR100496086B1 (en) | Process for the preparation of oral pharmaceutical compositions comprising bisphosphonates | |
| JP3550091B2 (en) | Fumaric acid micro tablets | |
| CN102225047B (en) | Enteric solid oral dosage form of bisphosphonate containing a chelating agent | |
| US20070104786A1 (en) | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate | |
| US20050026871A1 (en) | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative | |
| SK171899A3 (en) | Film-coated tablet for improved upper gastrointestinal tract safety | |
| US6676965B1 (en) | Enteric coated formulation for bisphosphonic acids and salts thereof | |
| CN103842330A (en) | Choline salt of an anti - inflammatory substituted cyclobutenedione compound | |
| JP2006514695A (en) | Method for enhancing the overall utilization efficiency of alendronate or other bisphosphonates by pre-dose administration of vitamin D derivatives | |
| US8697124B2 (en) | Solid dosage form of coated bisphosphonate particles | |
| AU8819598A (en) | A process for the preparation of solid oral dosage forms comprising alendronic acid | |
| GB2130087A (en) | Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions | |
| CN100411613C (en) | Fast releasing solid omeprazole prepn and its prepn process | |
| CN117717557A (en) | Preparation method of drug composition containing ibutenib | |
| MXPA01003407A (en) | Process for the preparation of oral pharmaceutical compositions comprising biphosphonates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |